Anagrelide is a phosphodiesterase 3 pde3 inhibitor and may cause vasodilation, tachycardia, palpitations, and congestive heart failure. Zemdri plazomicin injection zemdri official website. A healthcare provider may recommend jakafi to people who have intermediaterisk or highrisk myelofibrosis. Hepatotoxicity see full prescribing information for complete boxed warning. Jakafi ruxolitinib tablets, for oral use initial u. Adverse reactions the most common hematologic adverse. In some cases, health care professionals may use the generic drug name ruxolitinib when referring to the trade name jakafi. Highlights of prescribing information these highlights do not include all the information needed to use injectafer safely and effectively. This leaflet is part iii of a threepart product monograph. Jakafi sgm p2016 cvs caremark is an independent company that provides pharmacy benefit management services to carefirst bluecross blueshield and carefirst bluechoice, inc. Votrient pazopanib tablets, for oral use initial u.
The printed package leaflet of the medicinal product must state the name and. The apparent volume of distribution at steady state ranged from 43 to 90 l. The nccn drugs and biologics compendium nccn compendium. First and only fdaapproved treatment for potentially life threatening blood cancer. Carefirst bluecross blueshield is the shared business name of carefirst of maryland, inc. Twice weekly 2056mgm2 regimen by 30minute infusion kyprolis is administered intravenously as a 30minute infusion on two consecutive days, each week for threeweeks followed by a 12day rest period as shown in table2. Fda approves incytes jakafitm ruxolitinib for patients with. Highlights of prescribing information tafinlar with. Indication for which you are prescribing jakafi ruxolitinib for this patient.
Alecensa alectinib capsules, for oral use initial u. Talk to your healthcare provider if this is a concern for you. Your healthcare provider may do a pregnancy test before you start treatment with balversa. Jakafi ruxolitinib dosing, indications, interactions, adverse effects. Highlights of prescribing information do not coadminister. Fatal andor serious and severe diarrhea or colitis occurred in 14% to 19% of zydeligtreated patients.
Official hcp website for zemdri plazomicinan antibiotic indicated for the treatment of complicated urinary tract infections cuti, including pyelonephritis. Highlights of prescribing information these highlights do not include all the information needed to use janumet safely and effectively. Refer to the dexamethasone prescribing information for other information on that product. Highlights of prescribing information these highlights do not include all the information needed to use votrient safely and effectively. Feb 01, 2020 jakafi is indicated for treatment of polycythemia vera pv in adults who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi fda prescribing information, side effects and uses. Highlightsof prescribing information kyprolis safely and. Zelboraf is not indicated for treatment of patients with wildtype braf melanoma. Highlights of prescribing information patients who have known.
Highlights of prescribing information these highlights do not include all the information needed to use alecensa safely and effectively. Intravitreal injections, including those with iluvien, have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Highlights of prescribing information patients with highrisk. Janumetsitagliptinand metformin hydrochloride tablets, for oral use initial u. Accelerated approval was granted for fl and sll based on. Jadenu deferasirox tablets, for oral use jadenu sprinkledeferasirox granules, for oral use initial u. Fatal andor serious and severe diarrhea or colitis occurred in 14% to 20% of zydeligtreated patients. Patient information jakafi jakahfye ruxolitinib tablets. The mean baselinecorrected serum calcium for the aredia 60mg and etidronate disodium groups were. Jakafi ruxolitinib tablets prescribing information. Feb 26, 2020 tapering of jakafi may be considered after 6 months of treatment in patients with response who have discontinued therapeutic doses of corticosteroids. Polycythemia vera o jakafi is indicated for treatment of patients with polycythemia vera who have had an inadequate response. Medscape indication dosing for jakafi ruxolitinib, frequencybased adverse.
Jakafi ruxolitinib jakafi fep clinical rationale rationale for inclusion in pa program background jakafi is a janus kinase 1 and 2 inhibitor approved by the fda for the treatment of intermediate or highrisk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis. Combined 2 month dose taper language into a note per prior authorization team request. These highlights do not include all the information needed to use jakafi safely and effectively. It is a cardioprotective agent for use in conjunction with doxorubicin.
Program prior authorization medication jakafi ruxolitinib issue date 52016 pharmacy and therapeutics approval date 32017 effective date 52017. Duration oftherapy is based on recovery from neutropenia or immunosuppression. Jakafi should be avoided in patients with hepatic impairment with platelet counts less than 100 x 10. Equilibrate the refrigerated vial of noxafilposaconazoleinjectionto room temperature. Jakafi is approved for use in adults only, and works by blocking the abnormal formation of blood. Connecticare considers jakafi medically necessary when. The recommended starting dose of jakafi is based on platelet count table 1. Taper jakafi by one dose level approximately every 8 weeks 10 mg twice daily to 5 mg twice daily to 5 mg once daily. Jakafi ruxolitinib 5mg tablets intermediate or highrisk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis and postessential thrombocythemia myelofibrosis. Doses may be titrated based on safety and efficacy. Jakafi polycythemia vera, myelofibrosis, acute graft. Thirty patients were randomized to receive aredia and 35 to receive etidronate disodium.
Inlyta axitinib tablets 2ndline mrcc treatment safety. Learn about jakafi ruxolitinib used to treat adults with polycythemia vera who have taken hydroxyurea and it did not work well enough or they could not tolerate it, adults with certain types of myelofibrosis, and to treat adults and children 12 years of age and older with acute graftversushost disease who have taken corticosteroids and they did not work well enough. Jakafi is indicated for treatment of intermediate or highrisk myelofibrosis mf, including primary mf, postpolycythemia vera mf and postessential thrombocythemia mf in adults. Zinecard dexrazoxane for injection description zinecard dexrazoxane for injection is a sterile, pyrogenfree lyophilizate intended for intravenous administration. Aggressive squamous cell carcinoma in a patient on the. Jakafi is indicated for treatment of patients with polycythemia vera pv who have had an inadequate response to or are intolerant of hydroxyurea. Chemically, dexrazoxane is s4,41methyl1,2ethanediylbis2,6piperazinedione. Inlyta may cause fertility problems in males and females, which may affect your ability to have a child. Anagrelide fda prescribing information, side effects and uses. The starting dose of jakafi is based on patients baseline platelet count. This prescription medicine can help reduce an enlarged spleen and relieve symptoms in people who have this rare disease of the bone marrow. The recommended starting dose of jakafi is based on platelet count. Prescribing information, which includes a more complete discussion of the risks associated with jakafi.
Jakafi ruxolitinib is a kinase inhibitor indicated for treatment of patients with intermediate or highrisk myelofibrosis, including primary myelofibrosis pmf, post polycythemia vera myelofibrosis and postessential thrombocythemia myelofibrosis. Case report aggressive squamous cell carcinoma in a patient on the janus kinase inhibitor ruxolitinib nader aboulfettouh, bs, and rajiv i. Jakafi is indicated for treatment of patients with polycythemia vera who have had an inadequate. Monitor for the development of severe diarrhea or colitis. Other drugs that inhibit pde3 have caused decreased survival when compared with placebo in patients with class iiiiv congestive heart failure see drug interactions 7.
Jakafi ruxolitinib is an fdaapproved treatment for adults with intermediate or highrisk myelofibrosis, for adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea and for adult and pediatric patients 12 years and older with acute graftversushost disease gvhd who are steroid refractory. Jakafi is indicated for treatment of steroid refractory acute graftversushost disease. Jakafi ruxolitinib is a kinase inhibitor indicated for treatment of patients with. Enzalutamides kinetics can be described by a linear 2compartment model with firstorder absorption. It is an oral receptor tyrosine kinase inhibitor for more detail, see how this drug works, below. Tell your healthcare provider about all the medicines you take, including prescription and overthecounter medicines, vitamins, and herbal supplements. Find the patient information for jakafi ruxolitinib, which is indicated for the treatment of adults with intermediate or highrisk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis. You should use effective birth control during treatment and for 1 month after the last dose of balversa. Jakafi is the trade for the generic drug ruxolitinib. Jakafi is indicated for treatment of patients with intermediate or highrisk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis and postessential thrombocythemia myelofibrosis. Jakafi is indicated for treatment of steroidrefractory acute graftversushost disease gvhd in adult and pediatric patients 12 years and older.
1438 723 1201 235 644 457 1071 1199 1145 113 442 180 867 1453 682 461 1129 249 1019 1458 811 514 1269 1105 1150 1364 819 267 161 1459